from what I gather listening to the call..
1) Strengthened balance sheet by converting $10 million in CRG debt to equity
2) Sales do NOT include BARDA (since T2 received the FDA clearance for the Biothreat panel)
3) Large shortfall due to backorders (Hence why they are ramping up development by hiring new people)
4) Expecting Q4 to be far more productive with fulfilling backorders and new sales
5) Products take time to develop to meet demand
6) Shifted focus on supply chain problems during Q3 which should clear the backorders by end of Q4
7) Ramping up conferences, university trials to produce sales
8) Another 510k submission to detect the bacteria that is the major cause of Lyme disease in the US
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
FiReBiTriXiE : The company is not bad and it’s not dead but it’s definitely risky being over $10 a share now like I said lotta meat on the bones and they don’t have very good sentiment right now. Lotta people lost money here. I don’t think people should’ve sold but obviously a ton did for losses too. I’m sure. I don’t blame them either.
scooobydooOP FiReBiTriXiE: I hear you, but at the same time I don't think they really care as much for retail $$ as opposed to larger institutional investors.
The major difference between retail and large institutions is that retail will gamble, day trade while larger investors knows that products like this have a future but the timeline to produce results is a long process.
If I was T2, I couldn't care much for retail because retail is ..well basically known to buy and sell, swing/day trade it making profits for themselves, instead of thinking about the company.
J L 7 2 FiReBiTriXiE: This loss isn't that big. You see, the day before yesterday, 4000% of people developed overnight and 60% of their net worth disappeared the next day